Genetic and companion testing takes a village, according to Jan Berger, MD, MJ, president and chief executive officer of Health Intelligence Partners and editor-in-chief of The American Journal of Pharmacy Benefits.
Genetic and companion testing takes a village, according to Jan Berger, MD, MJ, president and chief executive officer of Health Intelligence Partners and editor-in-chief of The American Journal of Pharmacy Benefits.
Not only do the providers need to be in line, but so do the genetic counselors — if they’re available — and the industry is struggling with that as well as knowing the right processes to go through, she explained.
“So I think we need to come to a consensus on the right timing and the right process to put this all together to get the outcomes we’re looking for,” Dr Berger said.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More